Adenocarcinoma: Difference between revisions

	WikiDoc Resources for Adenocarcinoma
Articles
Most recent articles on Adenocarcinoma Most cited articles on Adenocarcinoma Review articles on Adenocarcinoma Articles on Adenocarcinoma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Adenocarcinoma Images of Adenocarcinoma Photos of Adenocarcinoma Podcasts & MP3s on Adenocarcinoma Videos on Adenocarcinoma
Evidence Based Medicine
Cochrane Collaboration on Adenocarcinoma Bandolier on Adenocarcinoma TRIP on Adenocarcinoma
Clinical Trials
Ongoing Trials on Adenocarcinoma at Clinical Trials.gov Trial results on Adenocarcinoma Clinical Trials on Adenocarcinoma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Adenocarcinoma NICE Guidance on Adenocarcinoma NHS PRODIGY Guidance FDA on Adenocarcinoma CDC on Adenocarcinoma
Books
Books on Adenocarcinoma
News
Adenocarcinoma in the news Be alerted to news on Adenocarcinoma News trends on Adenocarcinoma
Commentary
Blogs on Adenocarcinoma
Definitions
Definitions of Adenocarcinoma
Patient Resources / Community
Patient resources on Adenocarcinoma Discussion groups on Adenocarcinoma Patient Handouts on Adenocarcinoma Directions to Hospitals Treating Adenocarcinoma Risk calculators and risk factors for Adenocarcinoma
Healthcare Provider Resources
Symptoms of Adenocarcinoma Causes & Risk Factors for Adenocarcinoma Diagnostic studies for Adenocarcinoma Treatment of Adenocarcinoma
Continuing Medical Education (CME)
CME Programs on Adenocarcinoma
International
Adenocarcinoma en Espanol Adenocarcinoma en Francais
Business
Adenocarcinoma in the Marketplace Patents on Adenocarcinoma
Experimental / Informatics
List of terms related to Adenocarcinoma

VisualWikitext

Latest revision as of 17:20, 27 May 2019

Template:DiseaseDisorder infobox

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Adenocarcinoma is a form of carcinoma that originates in glandular tissue. To be classified as adenocarcinoma, the cells do not necessarily need to be part of a gland, as long as they have secretory properties. This form of carcinoma can occur in some higher mammals, including humans.^[1] The term adenocarcinoma is derived from 'adeno' meaning 'pertaining to a gland' and 'carcinoma', which describes a cancer that has developed in the epithelial cells. It can first present as an adenoma (a glandular tumor that is benign).

Pathophysiology

Examples of tissues where adenocarcinomas may arise:

Breast cancer
Colon cancer
Lung cancer
Prostate cancer
Stomach cancer
Pancreatic cancer (99% of pancreatic cancers are ductal adenocarcinomas [2])
Cervical cancer
Vaginal cancer

Physical Examination

Adenocarcinoma-In The Submandibular Salivary Glands

Adenocarcinoma-In The Submandibular Salivary Glands
Adapted from Dermatology Atlas
Adenocarcinoma-In The Submandibular Salivary Glands
Adapted from Dermatology Atlas
Adenocarcinoma-In The Submandibular Salivary Glands
Adapted from Dermatology Atlas

Differential Diagnosis

Diseases	Risk factors/Epidemiology	History	Clinical Findings	Gross Pathology	Histopathology	Immunohistochemistry	Lab Findings	Imaging	Metastatic Potential	Gold Standard	Additional Findings
Head & Neck Cancer
Paranasal Sinus Cancer
Lung Cancer
Breast Cancer
Esophageal Cancer
Diseases	Risk factors/Epidemiology	History	Clinical Findings	Gross Pathology	Histopathology	Immunohistochemistry	Lab Findings	Imaging	Metastatic Potential	Gold Standard	Additional Findings
Gastric Cancer
Pancreatic Cancer
Small Bowel Cancer
Colorectal Cancer
Appendix Cancer
Diseases	Risk factors/Epidemiology	History	Clinical Findings	Gross Pathology	Histopathology	Immunohistochemistry	Lab Findings	Imaging	Metastatic Potential	Gold Standard	Additional Findings
Gallbladder Cancer
Anal Cancer
Cervical Cancer
Vaginal Cancer
Endometrial Cancer
Vulvar Cancer
Diseases	Risk factors/Epidemiology	History	Clinical Findings	Gross Pathology	Histopathology	Immunohistochemistry	Lab Findings	Imaging	Metastatic Potential	Gold Standard	Additional Findings
Prostate Cancer
Testicular Cancer
Urinary Bladder Cancer
Urethral Cancer
Metastatic Cancer
Cancer of Unknown Primary

References

↑ Fauquier, D.A., Gulland, F.M.D.,(Marine Mammal Center), Haulena, M., Spraker, T., ‘’Biliary adenocarcinoma in a stranded Northern elephant seal (‘’Mirounga angustirortsis’‘)’‘, Journal of Wildlife Diseases 39(3):723-726 (2003)

Template:Epithelial neoplasms

de:Adenokarzinom gl:Adenocarcinoma nl:Adenocarcinoom

Template:WikiDoc Sources

[1] Fauquier, D.A., Gulland, F.M.D.,(Marine Mammal Center), Haulena, M., Spraker, T., ‘’Biliary adenocarcinoma in a stranded Northern elephant seal (‘’Mirounga angustirortsis’‘)’‘, Journal of Wildlife Diseases 39(3):723-726 (2003)

[1]

@@ Line 29: / Line 29: @@
 * [[Cervical cancer]]
 * [[Vaginal cancer]]
-===Gross Pathology===
-<gallery>
-Image:gastcarc_enface.jpg|This cancer presented in a 40-year-old woman complaining of abdominal pain. Endoscopically it was a "very suspicious" ulcer. Biopsy showed diffusely infiltrating signet ring cell adenocarcinoma. These are gross photos of the subtotal gastrectomy specimen. The photo above is a seen face view of the ulcer. The pyloric margin is to the left. The ulcer is on the lesser curvature.
-Image:Gastcarc xsec.jpg|This is a longitudinal section cut in the plane of the lesser curvature. The pylorus is to the left. Note several prominent nodes of the lesser omentum; these contained metastatic cancer.
-</gallery>
 ==Physical Examination==
@@ Line 132: / Line 125: @@
 | style="background: #F5F5F5; padding: 5px;" |
 | style="background: #F5F5F5; padding: 5px;" |
+|-
+|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
+! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Diseases
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Risk factors/Epidemiology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | History
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Clinical Findings
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gross Pathology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Histopathology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Immunohistochemistry
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Lab Findings
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Imaging
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Metastatic Potential
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gold Standard
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Additional Findings
 |-
 | style="background: #DCDCDC; padding: 5px; text-align: center;" | Gastric Cancer
@@ Line 186: / Line 193: @@
 |-
 | style="background: #DCDCDC; padding: 5px; text-align: center;" | Appendix Cancer
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+|-
+|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
+! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Diseases
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Risk factors/Epidemiology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | History
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Clinical Findings
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gross Pathology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Histopathology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Immunohistochemistry
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Lab Findings
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Imaging
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Metastatic Potential
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gold Standard
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Additional Findings
+|-
+| style="background: #DCDCDC; padding: 5px; text-align: center;" | Gallbladder Cancer
 | style="background: #F5F5F5; padding: 5px;" |
 | style="background: #F5F5F5; padding: 5px;" |
@@ Line 262: / Line 296: @@
 | style="background: #F5F5F5; padding: 5px;" |
 | style="background: #F5F5F5; padding: 5px;" |
+|-
+|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
+! rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Diseases
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Risk factors/Epidemiology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | History
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Clinical Findings
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gross Pathology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Histopathology
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Immunohistochemistry
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Lab Findings
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Imaging
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Metastatic Potential
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Gold Standard
+! colspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" | Additional Findings
 |-
 | style="background: #DCDCDC; padding: 5px; text-align: center;" | Prostate Cancer
@@ Line 276: / Line 324: @@
 | style="background: #F5F5F5; padding: 5px;" |
 |-
-| style="background: #DCDCDC; padding: 5px; text-align: center;" | Bladder Cancer
+| style="background: #DCDCDC; padding: 5px; text-align: center;" | Testicular Cancer
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+|-
+| style="background: #DCDCDC; padding: 5px; text-align: center;" | Urinary Bladder Cancer
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+|-
+| style="background: #DCDCDC; padding: 5px; text-align: center;" | Urethral Cancer
 | style="background: #F5F5F5; padding: 5px;" |
 | style="background: #F5F5F5; padding: 5px;" |
@@ Line 290: / Line 364: @@
 |-
 | style="background: #DCDCDC; padding: 5px; text-align: center;" | Metastatic Cancer
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+| style="background: #F5F5F5; padding: 5px;" |
+|-
+| style="background: #DCDCDC; padding: 5px; text-align: center;" | Cancer of Unknown Primary
 | style="background: #F5F5F5; padding: 5px;" |
 | style="background: #F5F5F5; padding: 5px;" |